TOIHealthcare · Medical Care FacilitiesThe 5 Wall Street analysts covering The Oncology Institute, Inc. hold a median 12-month price target of $8 — +55.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores The Oncology Institute, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Volatility (16): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own The Oncology Institute, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on TOI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +55.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | BTIG | Maintains | Buy | $8.00 → $9.00 |
| 6 July 2026 | Lake Street | Initiates | Buy | $10 |
| 17 June 2026 | Needham | Maintains | Buy | — |
| 8 June 2026 | BTIG | Maintains | Buy | — |
| 13 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 Mar 2026 | Needham | Reiterates | Buy | — |
| 9 Mar 2026 | BTIG | Reiterates | Buy | — |
| 9 Mar 2026 | Needham | Reiterates | Buy | — |
| 25 Nov 2025 | Needham | Initiates | Buy | — |
| 21 Oct 2025 | BTIG | Reiterates | Buy | — |
| 16 July 2025 | B. Riley Securities | Initiates | Buy | — |
| 26 Feb 2024 | Jefferies | Assumes | Buy | $2.50 |
| 16 June 2023 | Guggenheim | Maintains | Buy | — |
| 20 Mar 2023 | Guggenheim | Maintains | Neutral | — |
| 11 Nov 2022 | Guggenheim | Maintains | Buy | — |
| 15 Aug 2022 | Jefferies | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 72% of US stocks
Cheaper than 98% of US stocks
Cheaper than 89% of US stocks
Higher than 84% of US stocks
Higher than 74% of US stocks
Higher than 16% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 99% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TOI appears on the weeks it earns a place.
The Oncology Institute, Inc., one of the largest value-based oncology groups in the United States, announced that it has rebranded to Starling Oncology, Inc.
Why it matters — A TOI watcher would care because the company's corporate identity is changing, which could affect how it is recognized and followed in the market.
The Oncology Institute announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 5:00 p.m. the same day.
Why it matters — The earnings release and conference call will provide the company's latest financial results and operational update for the second quarter of 2026.
The 5 Wall Street analysts covering The Oncology Institute, Inc. have a median 12-month price target of $8, with estimates ranging from $7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering The Oncology Institute, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Oncology Institute, Inc. 70 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, The Oncology Institute, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +55.9% from the last close, and Ticker Nerd's factor model ranks The Oncology Institute, Inc. 70 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Oncology Institute, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TOI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $10 over the next 12 months.
The Oncology Institute, Inc. returned +37.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
The Oncology Institute, Inc. is a value-based community oncology group providing comprehensive cancer care treatment services across multiple settings.
The most recent item we track (GlobeNewsWire, 3 Aug 2026): "The Oncology Institute Rebrands as Starling Oncology". The Oncology Institute, Inc., one of the largest value-based oncology groups in the United States, announced that it has rebranded to Starling Oncology, Inc.
The Oncology Institute, Inc. is a value-based community oncology group providing comprehensive cancer care treatment services across multiple settings. Operating through three primary segments—Dispensary, Patient Care, and Clinical Trials and Other—the company delivers specialized oncology services including infusion centers, in-house pharmaceutical dispensary, outpatient blood transfusions, outpatient stem cell transplants, financial counseling, clinical trials, comprehensive laboratory testing, and end-of-life counseling. With over 100 employed clinicians and more than 800 team members operating across numerous clinic locations, The Oncology Institute serves a large patient population with evidence-based, high-quality cancer care. Founded in 2007 and headquartered in Cerritos, California, the company focuses on advancing oncology through value-based care models designed to improve patient outcomes while optimizing healthcare delivery in community settings rather than traditional hospital environments.
CEO Dr. Daniel Virnich FACHE, M.B.A., M.D. · 641 employees · United States · https://theoncologyinstitute.com